<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411983</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 006</org_study_id>
    <nct_id>NCT00411983</nct_id>
  </id_info>
  <brief_title>A Long-term Follow-up of the HIV-NAT Cohort</brief_title>
  <official_title>A Long-term Follow-up Study for HIV-infected Individuals Who Have Participated in HIV-NAT Study Protocols</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With HIV/AIDS increasingly considered a chronic disease, 24-, or 48-week data from
      antiretroviral studies are no longer sufficient. Only with long-term follow-up and outcome
      data will shed some much-needed light on the answers of questions that have stumped us for
      several years. Data from a large observational cohort of patients treated with combination
      antiretroviral therapy will provide further insights into the long-term safety and durability
      of various antiretroviral therapeutic approached, the efficacy of HIV viral load and CD4 cell
      counts as predictors of disease progression and mortality, and the importance of adherence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      To collect and evaluate long-term clinical outcomes of HIV infected participants previously
      enrolled in HIV-NAT trials.

      Secondary Objective:

      To Assess:

        1. Long-term consequences of initiation of antiretroviral as predicted by baseline CD4 cell
           count and/or baseline plasma HIV RNA level

        2. Incidence of lipodystrophy and other metabolic complications in three different groups
           of patients initially treated with NRTI-based regimens, NNRTI-based regimens, or
           PI-based regimens

        3. Class-specific incidence of lipodystrophy and metabolic complications such as d4T versus
           AZT, nevirapine versus efavirenz and individual PIs (IDV, SQV, Kaletra, and atazanavir)

        4. Resistance profiles in patients on different antiretroviral regimens

        5. Long-term consequences of antiretroviral agents on cardiovascular, renal, hepatic, and
           endocrine function, skin, gastrointestinal system and urogentital tract

        6. Incidence of opportunistic infections or malignancy including hepatocarcinoma in
           patients with HIV/HCV or HIV/HBV co-infection

        7. Immune recovery syndrome

        8. Adherence to different antiretroviral regimens

        9. Quality of life
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HIV infection</measure>
    <time_frame>30 years</time_frame>
    <description>This cohort will collect various information such as but not limited to:
comorbidity, mortality, cardiovascular, neurological clinical data, treatment history, serious adverse events, PBMCs, clinical outcomes, virological outcomes, resistance, failure, aging, other opportunistic infections, etc</description>
  </primary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>HIV Infections</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PBMC collection once a year
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All HIV infected adult patients from HIV-NAT.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected patients( children and adults) previously participated HIV-NAT studies

          -  HIV infected patients( children and adults) currently participate in HIV-NAT trials

          -  Able to provide written consent

        Exclusion Criteria:

          -  Unable to provide written consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Praphan Phanuphak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIV-NAT, Thai Red Cross AIDS Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anchalee Avihingsanon, MD, PhD</last_name>
    <phone>66 2 2557334-5</phone>
    <phone_ext>107</phone_ext>
    <email>anchalee.a@hivnat.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Kerr, PhD</last_name>
    <phone>66 2 2557334-5</phone>
    <phone_ext>138</phone_ext>
    <email>s.kerr@unsw.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HIV-NAT, Thai Red Cross AIDS Research Center</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Praphan Phanuphak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <results_reference>
    <citation>Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004 May 21;18(8):1169-77.</citation>
    <PMID>15166532</PMID>
  </results_reference>
  <results_reference>
    <citation>Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS. 2003 Oct 17;17(15):2191-9.</citation>
    <PMID>14523276</PMID>
  </results_reference>
  <results_reference>
    <citation>Avihingsanon A, Kerr SJ, Punyawudho B, van der Lugt J, Gorowara M, Ananworanich J, Lange JM, Cooper DA, Phanuphak P, Burger DM, Ruxrungtham K. Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients. AIDS Res Hum Retroviruses. 2013 Dec;29(12):1541-6. doi: 10.1089/aid.2013.0069. Epub 2013 Oct 2.</citation>
    <PMID>24088045</PMID>
  </results_reference>
  <results_reference>
    <citation>Clarke A, Kerr S, Honeybrook A, Cooper DA, Avihingsanon A, Duncombe C, Phanuphak P, Ruxrungtham K, Ananworanich J, Kaldor J. Adherence and Risk Behaviour in Patients with HIV Infection Receiving Antiretroviral Therapy in Bangkok. Open Virol J. 2012;6:23-8. doi: 10.2174/1874357901206010023. Epub 2012 Feb 24.</citation>
    <PMID>22423306</PMID>
  </results_reference>
  <results_reference>
    <citation>Nuesch R, Srasuebkul P, Ananworanich J, Ruxrungtham K, Phanuphak P, Duncombe C; HIV-NAT Study Team. Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother. 2006 Sep;58(3):637-44.</citation>
    <PMID>16895939</PMID>
  </results_reference>
  <results_reference>
    <citation>Avihingsanon A, Tongkobpetch S, Kerr SJ, Punyawudho B, Suphapeetiporn K, Gorowara M, Ruxrungtham K, Shotelersuk V. Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. J Acquir Immune Defic Syndr. 2015 May 1;69(1):e36-7. doi: 10.1097/QAI.0000000000000540.</citation>
    <PMID>25622064</PMID>
  </results_reference>
  <results_reference>
    <citation>Kerr SJ, Punyawudho B, Thammajaruk N, Colbers A, Chaiyahong P, Phonphithak S, Sapsirisavat V, Ruxrungtham K, Burger DM, Avihingsanon A. Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2015 Apr;31(4):368-74. doi: 10.1089/AID.2014.0249. Epub 2014 Dec 17.</citation>
    <PMID>25384393</PMID>
  </results_reference>
  <results_reference>
    <citation>Avihingsanon A, Ramautarsing RA, Suwanpimolkul G, Chetchotisakd P, Bowonwatanuwong C, Jirajariyavej S, Kantipong P, Tantipong H, Ohata JP, Suankratay C, Ruxrungtham K, Burger DM. Ergotism in Thailand caused by increased access to antiretroviral drugs: a global warning. Top Antivir Med. 2014 Jan;21(5):165-8.</citation>
    <PMID>24531557</PMID>
  </results_reference>
  <results_reference>
    <citation>Avihingsanon A, Jitmitraparp S, Tangkijvanich P, Ramautarsing RA, Apornpong T, Jirajariyavej S, Putcharoen O, Treeprasertsuk S, Akkarathamrongsin S, Poovorawan Y, Matthews GV, Lange JM, Ruxrungtham K; HIV-NAT125 study team. Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels. J Gastroenterol Hepatol. 2014 Sep;29(9):1706-14. doi: 10.1111/jgh.12613.</citation>
    <PMID>24730732</PMID>
  </results_reference>
  <results_reference>
    <citation>Wattanakul T, Avihingsanon A, Manosuthi W, Punyawudho B. Population pharmacokinetics of nevirapine in Thai HIV-infected patients. Antivir Ther. 2014;19(7):651-60. doi: 10.3851/IMP2741. Epub 2014 Feb 6.</citation>
    <PMID>24504545</PMID>
  </results_reference>
  <results_reference>
    <citation>Durier N, Ananworanich J, Apornpong T, Ubolyam S, Kerr SJ, Mahanontharit A, Ferradini L, Ruxrungtham K, Avihingsanon A. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality. Clin Infect Dis. 2013 Jul;57(1):147-55. doi: 10.1093/cid/cit173. Epub 2013 Mar 19.</citation>
    <PMID>23511301</PMID>
  </results_reference>
  <results_reference>
    <citation>Praditpornsilpa K, Avihingsanon A, Chaiwatanarat T, Chaiyahong P, Wongsabut J, Ubolyam S, Chulakadabba A, Avihingsanon Y, Ruxrungtham K, Tunsanga K, Eiam-Ong S, Phanuphak P. Comparisons between validated estimated glomerular filtration rate equations and isotopic glomerular filtration rate in HIV patients. AIDS. 2012 Sep 10;26(14):1781-8. doi: 10.1097/QAD.0b013e328356480d. Erratum in: AIDS. 2013 Mar 13;27(5):853.</citation>
    <PMID>22713478</PMID>
  </results_reference>
  <results_reference>
    <citation>Kerr SJ, Duncombe C, Avihingsanon A, Ananworanich J, Boyd M, Sopa B, Medtech B, Chuenyam T, Cooper DA, Lange JM, Phanuphak P, Ruxrungtham K. Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. J Int Assoc Physicians AIDS Care (Chic). 2007 Mar;6(1):36-46.</citation>
    <PMID>17329503</PMID>
  </results_reference>
  <results_reference>
    <citation>Avihingsanon A, Avihingsanon Y, Darnpornprasert P, Kerr S, Ungsedhapand C, Duncombe C, Ubolyam S, Ruxrungtham K, Phanuphak P. High prevalence of indinavir-associated renal complications in Thai HIV-infected patients. J Med Assoc Thai. 2006 Aug;89 Suppl 2:S21-7.</citation>
    <PMID>17044450</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2006</study_first_submitted>
  <study_first_submitted_qc>December 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2006</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic HIV infection</keyword>
  <keyword>long term cohort of HIV infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

